Prostate SABR With Intra-Prostatic SABR Boost

Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 35 Gy in 5 fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR detected nodule up to 50Gy. The pelvic lymph nodes and seminal vesicles will also receive 25 Gy in 5 weekly fractions.

Trial Details

NCT ID
NCT04212715
Phase
PHASE2
Sponsor
King Saud University
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Pelvic SABR with intra-prostatic SABR
Locations (sample)
  • Riyadh, Saudi Arabia|24.68773,46.72185

Key Eligibility Criteria

  • Histologically confirmed prostate adenocarcinoma
  • High-risk prostate cancer, defined as at least one of: T3, Gleason 8-10, OR PSA \> 20 ng/mL
  • Willing to give informed consent to participate in this clinical trial

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →